Viatris Inc
NASDAQ:VTRS

Watchlist Manager
Viatris Inc Logo
Viatris Inc
NASDAQ:VTRS
Watchlist
Price: 8.83 USD 2.79% Market Closed
Market Cap: 10.5B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one VTRS stock under the Base Case scenario is 24.64 USD. Compared to the current market price of 8.83 USD, Viatris Inc is Undervalued by 64%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VTRS Relative Value
Base Case
24.64 USD
Undervaluation 64%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

0.7
P/S
P/S
Price to Sales
0.7
vs History
61
vs Industry
76
Median 3Y
0.7
Median 5Y
0.8
Industry
2.4
Forward
0.7
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
1
Median 3Y
5.9
Median 5Y
5.5
Industry
21
Forward
3.9
More Details
4.7
P/OCF
P/OCF
Price to OCF
4.7
vs History
50
vs Industry
48
Median 3Y
4.5
Median 5Y
4.6
Industry
16.2
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
29
Median 3Y
10.4
Median 5Y
12.1
Industry
24
More Details
0.7
P/B
P/B
Price to Book Value
0.7
vs History
39
vs Industry
72
Median 3Y
0.6
Median 5Y
0.6
Industry
2
More Details
1.7
EV/S
EV/S
Enterprise Value to Sales
1.7
vs History
80
vs Industry
56
Median 3Y
1.8
Median 5Y
1.8
Industry
2.6
Forward
1.7
More Details
4.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.1
vs History
74
vs Industry
50
Median 3Y
4.2
Median 5Y
4.2
Industry
5.1
More Details
5.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
5.4
vs History
47
vs Industry
45
Median 3Y
5.3
Median 5Y
5.3
Industry
12.6
Forward
5.8
More Details
15.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
15.6
vs History
46
vs Industry
26
Median 3Y
12.8
Median 5Y
15
Industry
16
Forward
6.3
More Details
10.7
EV/OCF
EV/OCF
Enterprise Value to OCF
10.7
vs History
49
vs Industry
37
Median 3Y
10.5
Median 5Y
10.5
Industry
14.4
More Details
12.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
12.8
vs History
50
vs Industry
29
Median 3Y
12.6
Median 5Y
12.7
Industry
17.6
More Details
0.7
EV/IC
EV/IC
Enterprise Value to IC
0.7
vs History
23
vs Industry
70
Median 3Y
0.6
Median 5Y
0.6
Industry
1.8
More Details

Multiples Across Competitors

VTRS Competitors Multiples
Viatris Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Viatris Inc
NASDAQ:VTRS
10.4B USD 0.7 -2.8 5.4 15.6
US
Eli Lilly and Co
NYSE:LLY
683.5B USD 13.9 61.5 33.2 36.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
368.3B USD 4.1 16.9 12.4 16.2
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.6 19.2 13.3 15.3
CH
Roche Holding AG
SIX:ROG
207B CHF 3.4 25 9.4 11
CH
Novartis AG
SIX:NOVN
181.7B CHF 4.1 17 10 13.4
UK
AstraZeneca PLC
LSE:AZN
161.2B GBP 3.9 27.8 130.6 197
US
Merck & Co Inc
NYSE:MRK
191.6B USD 3 11 8.2 10
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
132.7B USD 2.1 16.8 7.3 10.3
P/E Multiple
Earnings Growth PEG
US
Viatris Inc
NASDAQ:VTRS
Average P/E: 24.4
Negative Multiple: -2.8 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
61.5
50%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
16.9
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.2
18%
1.1
CH
Roche Holding AG
SIX:ROG
25
32%
0.8
CH
Novartis AG
SIX:NOVN
17
17%
1
UK
AstraZeneca PLC
LSE:AZN
27.8
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11
17%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.8
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Viatris Inc
NASDAQ:VTRS
Average EV/EBITDA: 394.3
5.4
-1%
N/A
US
Eli Lilly and Co
NYSE:LLY
33.2
30%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.4
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
13%
1
CH
Roche Holding AG
SIX:ROG
9.4
5%
1.9
CH
Novartis AG
SIX:NOVN
10
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.6
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.2
8%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.3
2%
3.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Viatris Inc
NASDAQ:VTRS
Average EV/EBIT: 1 698.4
15.6
33%
0.5
US
Eli Lilly and Co
NYSE:LLY
36.2
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.2
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
15.3
14%
1.1
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
CH
Novartis AG
SIX:NOVN
13.4
10%
1.3
UK
AstraZeneca PLC
LSE:AZN
197
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
10%
1

See Also

Summary
VTRS intrinsic value, competitors valuation, and company profile.
DCF Valuation
VTRS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VTRS stock valuation using valuation multiples.
Wall Street Estimates
VTRS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VTRS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 258,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.